









Markets
/
Stocks
/
nasdaq-amrx
/

Amneal Pharmaceuticals Inc

AMRX

11.480USD

+0.110+0.97%

Close 11/10, 16:00（ET）Quotes delayed by 15 min

3.61BMarket Cap

611.12P/E TTM



Amneal Pharmaceuticals Inc

11.480

+0.110+0.97%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Amneal Pharmaceuticals Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amneal Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

34 / 159

Overall Ranking

86 / 4611

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.333

Target Price

+17.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amneal Pharmaceuticals Inc Highlights

StrengthsRisks

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.29% year-on-year.

Overvalued

The company’s latest PE is 644.22, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 147.18M shares, decreasing 12.53% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 60.20K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 8.36, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 784.51M, representing a year-over-year increase of 11.68%, while its net profit experienced a year-over-year increase of 1618.59%.

Score

Industry at a Glance

Previous score

8.36

Change



Financials

4.94

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.69

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.57

Key Metrics

Free cash flow

No Data

Amneal Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 8.19, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 644.22, which is 57.62% below the recent high of 1015.40 and 163.16% above the recent low of -406.91.

Score

Industry at a Glance

Previous score

8.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Amneal Pharmaceuticals Inc is 13.00, with a high of 14.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.333

Target Price

+17.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Amneal Pharmaceuticals Inc

AMRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 9.47, which is higher than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 12.39 and the support level at 10.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.36

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.210

Buy

RSI(14)

66.081

Neutral

STOCH(KDJ)(9,3,3)

80.367

Neutral

ATR(14)

0.413

High Vlolatility

CCI(14)

89.916

Neutral

Williams %R

21.164

Buy

TRIX(12,20)

0.514

Sell

StochRSI(14)

17.437

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

11.510

Sell

MA10

11.028

Buy

MA20

10.588

Buy

MA50

10.194

Buy

MA100

9.350

Buy

MA200

8.624

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 46.82%, representing a quarter-over-quarter decrease of 48.27%. The largest institutional shareholder is The Vanguard, holding a total of 17.90M shares, representing 5.69% of shares outstanding, with 19.27% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Patel (Tushar Bhikhubhai)

48.58M

-9.33%

Patel (Chintu)

25.62M

+1.39%

Patel (Dipan)

23.83M

Patel (Chirag K)

22.13M

Akram (Mahesh)

20.56M

-23.45%

The Vanguard Group, Inc.

Star Investors

17.49M

+11.34%

TPG Capital, L.P.

12.33M

Rubric Capital Management LP

11.71M

+9.08%

BlackRock Institutional Trust Company, N.A.

10.64M

-4.49%

Citadel Advisors LLC

5.62M

-24.92%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 8.65, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.37. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.